Inventor
Ezio Bonvini
Inventor
Potomac, MD, US
Overview
Patents· 26 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
A61KPreparations for medical, dental or toiletry purposes30%
Y02ATechnologies for adaptation to climate change3%
A01KAnimal husbandry1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
11,098,119Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof202111,078,279Combination therapy for the treatment of cancer202111,072,653LAG-3-binding molecules and methods of use thereof202111,028,183HER2/neu-specific antibodies and methods of using same202110,961,311B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof202110,954,301Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof202110,858,430Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof202010,787,521Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof202010,647,768Multi-chain polypeptide-containing tri-specific binding molecules202010,633,440Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens202010,633,443Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof202010,577,422PD-1-binding molecules and methods of use thereof202010,344,092Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof201910,160,806Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof201810,131,713HER2/neu-specific antibodies and methods of using same20189,932,400Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof20189,822,181'Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof'20179,469,692'HER2/neu-specific antibodies and methods of using same'20169,376,495'Deimmunized serum-binding domains and their use in extending serum half-life'20169,243,069'HER2/neu-specific antibodies and methods of using the same'20169,056,906'Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity'20158,946,387'FcγRIIB specific antibodies and methods of use thereof'20158,802,093'HER2/neu-specific antibodies and methods of using same'20148,663,634'Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity'20148,193,318'FcγRIIB specific antibodies and methods of use thereof'20128,187,593'FcγRIIB specific antibodies and methods of use thereof'2012Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2012–2021Patents assigned to MACROGENICS INC (26)· patent assignee history
2012–2016Patents assigned to BONVINI EZIO (7)· patent assignee history
2012–2015Patents assigned to KOENIG SCOTT (5)· patent assignee history
2012–2015Patents assigned to TUAILLON NADINE (4)· patent assignee history
2012–2016Based in Rockville, MD, US· patent location history
2014–2016Patents assigned to JOHNSON LESLIE S (4)· patent assignee history
2016–2021Based in Potomac, MD, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MACROGENICS INC | 26 | 2012–2021 |
| BONVINI EZIOself | 7 | 2012–2016 |
| KOENIG SCOTT | 5 | 2012–2015 |
| JOHNSON LESLIE S | 4 | 2014–2016 |
| TUAILLON NADINE | 4 | 2012–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Potomac, Maryland, US | 18 | 2016–2021 |
| Rockville, Maryland, US | 8 | 2012–2016 |